| Camrelizumab studied in …STUDIED_INderived200 of 288show all (up to 200) |
|---|
| → studied in | NCT05043688Phase 3 · active not recruiting Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05772273NA · recruiting PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT · 288 trials list this drug (88 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791602Phase 2 · active not recruiting Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer · 288 trials list this drug (88 active) | — | — | Malignant Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07787273Phase 2 · recruiting Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07057089Phase 2 · suspended Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) · 288 trials list this drug (88 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974944Phase 2 · terminated First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561308Phase 2 · recruiting Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04930315Phase 2 · completed SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06215677Phase 2 · active not recruiting Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer · 288 trials list this drug (88 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04706598Phase 1/Phase 2 · active not recruiting Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment · 288 trials list this drug (88 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07627620Phase 2 · not yet recruiting Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07622797Phase 2 · recruiting Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07618546NA · not yet recruiting A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05582499Phase 2 · recruiting Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy · 288 trials list this drug (88 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Early Stage Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05099848Phase 2 · completed A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04768075Phase 3 · completed Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05524168Phase 2 · active not recruiting SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04944914Phase 3 · recruiting Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07555860Phase 2 · not yet recruiting Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05213884Phase 2 · completed The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC · 288 trials list this drug (88 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07147101recruiting Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07530094Phase 2 · recruiting Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07527026Phase 2 · recruiting A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer · 288 trials list this drug (88 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07521605Phase 2 · not yet recruiting Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06654297Phase 1 · active not recruiting Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07320586Phase 2 · recruiting Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07466901NA · not yet recruiting A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03083041Phase 2 · completed A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07400094Phase 2 · not yet recruiting Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC · 288 trials list this drug (88 active) | — | — | Laryngeal Neoplasm,Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04067037Phase 2 · active not recruiting Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma · 288 trials list this drug (88 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03092895Phase 2 · completed A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC · 288 trials list this drug (88 active) | — | — | Biliary Tract Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06693128Phase 2 · active not recruiting Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04208347Phase 2/Phase 3 · active not recruiting Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05198609Phase 3 · active not recruiting Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04342910Phase 3 · recruiting Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07312578Phase 2 · enrolling by invitation Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04639180Phase 3 · active not recruiting A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07309419Phase 2/Phase 3 · not yet recruiting A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07266350not yet recruiting A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07157969Phase 2 · recruiting ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07238881Phase 2 · recruiting Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176002Phase 1/Phase 2 · active not recruiting Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. · 288 trials list this drug (88 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05367687Phase 2 · completed A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07191977Phase 2 · not yet recruiting Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03813784Phase 3 · completed A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy · 288 trials list this drug (88 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07159217Phase 2 · not yet recruiting Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer · 288 trials list this drug (88 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07100392Phase 2 · recruiting Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07105748Phase 2 · recruiting HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) · 288 trials list this drug (88 active) | — | — | Combined Hepatocellular Carcinoma and Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07107217Phase 2 · not yet recruiting Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer · 288 trials list this drug (88 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06323382recruiting Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06196671Phase 2 · not yet recruiting Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · 288 trials list this drug (88 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680988Phase 2 · completed A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05156970Phase 2 · completed Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC · 288 trials list this drug (88 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07053215NA · completed Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03777124Phase 2 · terminated Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06831175Phase 2 · recruiting Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma · 288 trials list this drug (88 active) | — | — | Adrenal Gland Neoplasm,Adrenal Cortical Carcinoma,Malignant Adrenal Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04521153Phase 2/Phase 3 · active not recruiting Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04195828Phase 2 · completed Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06632405Phase 2 · not yet recruiting A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC · 288 trials list this drug (88 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06288360Phase 2 · recruiting Neoadjuvant Immunochemotherapy in PD-L1-negative LACC · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05512481Phase 2 · recruiting Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma · 288 trials list this drug (88 active) | — | — | Melanoma,Acral Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04299581Phase 2 · recruiting Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma · 288 trials list this drug (88 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06849492Phase 2 · not yet recruiting HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer · 288 trials list this drug (88 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333561recruiting HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04649476Phase 2 · completed Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Oral Cavity Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06759090Phase 2 · not yet recruiting Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer · 288 trials list this drug (88 active) | — | — | Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05613478Phase 3 · recruiting Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05799183Phase 1 · terminated A SHR-1210 BE Study on Healthy Subjects · 288 trials list this drug (88 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878472Phase 2 · completed Neoadjuvant Immunotherapy for Resectable Gastric Cancer · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06516289Phase 2 · recruiting Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab · 288 trials list this drug (88 active) | — | — | BRCA Hereditary Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06731153Phase 2 · not yet recruiting JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC · 288 trials list this drug (88 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694324Phase 2 · not yet recruiting First-line Treatment of Advanced/unresectable DDLPS · 288 trials list this drug (88 active) | — | — | Soft Tissue Sarcoma,Dedifferentiated Liposarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 288 trials list this drug (88 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05003700Phase 2 · completed Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06289062Phase 2 · recruiting Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06288373Phase 2/Phase 3 · recruiting Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04070040Phase 2 · recruiting Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) · 288 trials list this drug (88 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05594095Phase 2 · recruiting SNF Platform Study of HR+/ HER2-advanced Breast Cancer · 288 trials list this drug (88 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04888429Phase 2 · recruiting Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06061276NA · recruiting bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04515615Phase 2 · active not recruiting Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06546280Phase 2 · unknown A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03417895Phase 2 · completed SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy · 288 trials list this drug (88 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06530082Phase 1 · not yet recruiting A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer · 288 trials list this drug (88 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06516445Phase 2 · unknown SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC · 288 trials list this drug (88 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06109207Phase 1 · unknown Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas · 288 trials list this drug (88 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04318730Phase 2 · unknown Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma · 288 trials list this drug (88 active) | — | — | Adrenal Cortical Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06485271recruiting A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06413992Phase 2 · recruiting Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer · 288 trials list this drug (88 active) | — | — | Endometrial Carcinoma,Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06376721Phase 1/Phase 2 · recruiting Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma · 288 trials list this drug (88 active) | — | — | T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06363825Phase 2 · recruiting A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03427827Phase 3 · unknown PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04674956Phase 3 · unknown A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer · 288 trials list this drug (88 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06231680Phase 2 · unknown Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) · 288 trials list this drug (88 active) | — | — | Malignant Lung Neoplasm,Esophageal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04830267Phase 2 · unknown The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06326736early Phase 1 · recruiting Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer · 288 trials list this drug (88 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02989922Phase 2 · completed A Study to Evaluate SHR-1210 in Subjects With Advanced HCC · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03558191Phase 2 · completed SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06304545Phase 2 · not yet recruiting Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab · 288 trials list this drug (88 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04627012completed Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05011227Phase 2 · unknown Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04694183Phase 2 · completed The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer · 288 trials list this drug (88 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05189483Phase 2 · unknown Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. · 288 trials list this drug (88 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03764293Phase 3 · completed A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05760378Phase 3 · recruiting Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. · 288 trials list this drug (88 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155425Phase 2 · completed PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma · 288 trials list this drug (88 active) | — | — | Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04720131Phase 2 · completed Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. · 288 trials list this drug (88 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03099382Phase 3 · completed Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer · 288 trials list this drug (88 active) | — | — | Esophageal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03472365Phase 2 · completed A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer · 288 trials list this drug (88 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04805736Phase 2 · completed Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer · 288 trials list this drug (88 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176885Phase 2 · recruiting Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer · 288 trials list this drug (88 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06170697Phase 2 · unknown Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04559607NA · unknown TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04379739Phase 2 · active not recruiting Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04393506Phase 1 · completed Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Malignant Lip and Oral Cavity Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05069857Phase 2 · recruiting Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients · 288 trials list this drug (88 active) | — | — | Oral Cavity Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05576272Phase 2/Phase 3 · unknown A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06124001Phase 1/Phase 2 · unknown Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05490485Phase 2 · unknown Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Skin Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06121557Phase 1 · recruiting Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer · 288 trials list this drug (88 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05624099Phase 2 · recruiting Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. · 288 trials list this drug (88 active) | — | — | Digestive System Neoplasm,Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05602935Phase 2 · active not recruiting Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study · 288 trials list this drug (88 active) | — | — | Neoplasm,Neoplasm by Site,Digestive System Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06048926NA · enrolling by invitation Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04346381Phase 2 · completed Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor · 288 trials list this drug (88 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789043Phase 3 · recruiting Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma · 288 trials list this drug (88 active) | — | — | Acral Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04156698Phase 2 · unknown Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Hypopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05981001Phase 1/Phase 2 · recruiting Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer · 288 trials list this drug (88 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04221516Phase 2 · unknown Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03871855Phase 1 · terminated A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors · 288 trials list this drug (88 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05447702Phase 2 · recruiting Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) · 288 trials list this drug (88 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05854849Phase 3 · recruiting Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05825443Phase 2 · recruiting Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821452Phase 2 · unknown Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04454905Phase 2 · unknown Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study · 288 trials list this drug (88 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04303741Phase 2 · unknown A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC · 288 trials list this drug (88 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816553Phase 2 · completed SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer · 288 trials list this drug (88 active) | — | — | Cervical Carcinoma,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04443309Phase 1/Phase 2 · unknown Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05097209Phase 2 · unknown Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05772208Phase 3 · recruiting Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05761470Phase 2 · recruiting Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02721589Phase 1 · completed A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects · 288 trials list this drug (88 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02738489Phase 1 · completed A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma · 288 trials list this drug (88 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02742935Phase 1 · completed A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects · 288 trials list this drug (88 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Malignant Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03085069Phase 2 · unknown A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC · 288 trials list this drug (88 active) | — | — | Neoplasm,Lung Neoplasm,Bronchogenic Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050760NA · unknown DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05697237NA · unknown Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma · 288 trials list this drug (88 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05669807Phase 2 · unknown Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691090Phase 3 · completed Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer · 288 trials list this drug (88 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05637268Phase 2 · unknown Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04459078Phase 2 · unknown Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma · 288 trials list this drug (88 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05042375Phase 3 · unknown A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05051865Phase 2 · unknown To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma · 288 trials list this drug (88 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04211090Phase 2 · unknown Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC · 288 trials list this drug (88 active) | — | — | Brain Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05559008Phase 1/Phase 2 · unknown A Umbrella Study in R/R PTCL Guided by Molecular Subtypes · 288 trials list this drug (88 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05610332Phase 3 · not yet recruiting Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05600998NA · unknown A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04420130NA · withdrawn A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009） · 288 trials list this drug (88 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05547737unknown Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03182673Phase 1 · terminated The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors · 288 trials list this drug (88 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05524974Phase 2 · not yet recruiting Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes · 288 trials list this drug (88 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05476380Phase 2 · unknown Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04355858Phase 2 · unknown Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer · 288 trials list this drug (88 active) | — | — | Malignant Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05472467Phase 2 · unknown Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05461235Phase 2 · unknown Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma · 288 trials list this drug (88 active) | — | — | Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03121716Phase 1 · completed A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03707509Phase 3 · unknown Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03827837Phase 2 · unknown Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors · 288 trials list this drug (88 active) | — | — | Urothelial Carcinoma,Renal Cell Carcinoma,Malignant Cervical Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05438706Phase 2 · unknown A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer · 288 trials list this drug (88 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05019534Phase 1 · unknown Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04878107Phase 2 · unknown SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04143984Phase 2 · unknown Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma · 288 trials list this drug (88 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05339581NA · unknown IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05342389Phase 2 · unknown Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer · 288 trials list this drug (88 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05320081Phase 2 · unknown Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma · 288 trials list this drug (88 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05322499Phase 2 · unknown Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05093140Phase 2 · unknown Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL · 288 trials list this drug (88 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03605706Phase 3 · unknown A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05225844Phase 2 · unknown An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal · 288 trials list this drug (88 active) | — | — | Malignant Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04390945Phase 2 · unknown Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer · 288 trials list this drug (88 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05193292Phase 2 · unknown Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer · 288 trials list this drug (88 active) | — | — | Intestinal Neoplasm,Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05183958Phase 2 · unknown A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer · 288 trials list this drug (88 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171309Phase 2 · unknown Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04506138Phase 1/Phase 2 · unknown Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04286958Phase 2 · unknown A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC · 288 trials list this drug (88 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05151549Phase 2 · unknown A Study of Carilizumab Combined With Concurrent Chemoradiotherapy · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05142865Phase 2 · unknown Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas · 288 trials list this drug (88 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05135364Phase 2 · unknown HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure · 288 trials list this drug (88 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05114707Phase 2 · unknown Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses · 288 trials list this drug (88 active) | — | — | Malignant Nasal Cavity Neoplasm,Malignant Paranasal Sinus Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111444Phase 2 · unknown Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma · 288 trials list this drug (88 active) | — | — | Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05097248Phase 2 · unknown Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy · 288 trials list this drug (88 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05095636Phase 2 · unknown Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer · 288 trials list this drug (88 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05088057Phase 2 · unknown Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer · 288 trials list this drug (88 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05049681Phase 3 · unknown Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell · 288 trials list this drug (88 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04426955Phase 3 · unknown Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer · 288 trials list this drug (88 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04943029Phase 2 · unknown Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04533490Phase 2 · unknown A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma · 288 trials list this drug (88 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04654403NA · unknown Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer · 288 trials list this drug (88 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04539600Phase 2 · unknown Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer · 288 trials list this drug (88 active) | — | — | Malignant Hypopharyngeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05005468Phase 2 · unknown A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. · 288 trials list this drug (88 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04974827Phase 2 · unknown A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer · 288 trials list this drug (88 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |